Indirect comparison of EGFR exon 19 deletion versus EGFR exon 21 L858R mutation in TKI therapy cohort in terms of HR for PFS.
收藏Figshare2015-12-02 更新2026-04-29 收录
下载链接：
https://figshare.com/articles/dataset/_Indirect_comparison_of_EGFR_exon_19_deletion_versus_EGFR_exon_21_L858R_mutation_in_TKI_therapy_cohort_in_terms_of_HR_for_PFS_/1170315
下载链接
链接失效反馈官方服务：
资源简介：
aHR19/21 of TKI represents HR19 exon deletion/exon 21 L858R mutation in TKI therapy cohort.Abbreviations: CI = confidence interval; EGFR = epidermal growth factor receptor; HR = Hazard ratio; PFS = progression-free survival; TKI = tyrosine kinase inhibitor.Indirect comparison of EGFR exon 19 deletion versus EGFR exon 21 L858R mutation in TKI therapy cohort in terms of HR for PFS.
TKI治疗队列中的aHR19/21指该队列中的HR19外显子缺失/21外显子L858R突变。
缩写说明：CI=置信区间（confidence interval, CI）；EGFR=表皮生长因子受体（epidermal growth factor receptor, EGFR）；HR=风险比（Hazard ratio, HR）；PFS=无进展生存期（progression-free survival, PFS）；TKI=酪氨酸激酶抑制剂（tyrosine kinase inhibitor, TKI）。
本数据集针对TKI治疗队列中EGFR 19外显子缺失与21外显子L858R突变患者，以无进展生存期对应的风险比为评价指标开展了间接比较分析。
创建时间：
2015-12-02
